Agios Pharmaceuticals has seen its fair value estimate cut from roughly $42.33 to about $32.13 per share, as analysts recalibrate expectations following mixed clinical outcomes and a more uncertain regulatory path. With the discount rate nudging up from ~7.00% to ~7.05% and long term revenue growth assumptions eased from ~124.9% to ~111.6%, the Street is signaling greater caution, even as some still see upside tied to potential approval for Pyrukynd in thalassemia. Stay tuned to see how you can track these shifting targets and stay ahead of the evolving Agios narrative.

Stay updated as the Fair Value for Agios Pharmaceuticals shifts by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Agios Pharmaceuticals.

???? Bullish Takeaways

Citi has initiated coverage with a Buy rating and a $38 target, arguing that Phase 3 data for Pyrukynd in thalassemia support approval and that the recent selloff on sickle cell disease data looks overdone, which implies meaningful upside from current levels if regulators agree.

H.C. Wainwright, despite cutting its target to $48 from $56, maintains a Buy rating and describes the post RISE UP selloff as overdone, pointing to precedent with Oxbryta and an absence of new safety issues as support for the long term growth case.

Across these bullish notes, analysts are effectively rewarding Agios for advancing multiple late stage assets and managing through clinical setbacks, but they still flag near term regulatory risk and uncertainty around the eventual commercial ramp as constraints on valuation.

???? Bearish Takeaways

RBC Capital has downgraded Agios to Sector Perform and cut its target to $28 from $57, citing that mitapivat in sickle cell disease is clearly active but fell short on key patient centric endpoints such as crises, hospitalization and fatigue, which reduces its view of the asset's value and commercial potential.

BofA has kept a Buy rating but slashed its target to $32 from $54, reflecting an uncertain regulatory and commercial path for mitapivat in sickle cell disease after only modest directional benefit on crises and fatigue, underscoring how much downside risk remains embedded in the current valuation.

JPMorgan has taken an even more conservative stance, maintaining a Neutral rating while lowering its target to $20 from $37 as it revises revenue expectations for mitapivat in sickle cell disease, pyruvate kinase deficiency and thalassemia, highlighting concerns about execution risk and the durability of the growth story.

Leerink and Oppenheimer, while focused on competitor Fulcrum, frame RISE UP as a relative setback for Agios by emphasizing non significant impacts on vaso occlusive crises and positioning Fulcrum's approach as potentially more compelling, which further pressures sentiment around Agios's long term market share and strategic positioning.

Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives or begin writing your own Narrative!

Agios reported topline 52-week RISE UP Phase 3 data in sickle cell disease, with mitapivat achieving a statistically significant hemoglobin response versus placebo, though results on crises, hospitalizations and fatigue were mixed, as most participants moved into a 216-week open-label extension.

The company announced that multiple new mitapivat datasets, including ENERGIZE T Phase 3 subgroup analyses in transfusion-dependent thalassemia and long-term follow-up data in transfusion-independent patients, will be presented at the ASH 2025 meeting in Orlando, which represents a key upcoming catalyst for the thalassemia program.

Agios highlighted preclinical data to be showcased at ASH 2025 indicating that mitapivat may protect against cardiomyopathy in a beta thalassemia mouse model, which could broaden the perceived cardiovascular benefit profile of the drug in hemolytic anemias.

The EMA's CHMP issued a positive opinion recommending approval of Pyrukynd mitapivat for anemia in adults with both transfusion-dependent and non transfusion-dependent alpha or beta thalassemia, with a final European Commission decision anticipated by early 2026, which could unlock a major new ex US revenue stream.

Fair Value: Reduced significantly from approximately $42.33 to about $32.13 per share, reflecting a more cautious outlook on long term cash flows.

Discount Rate: Risen slightly from about 7.00% to roughly 7.05%, implying a modest increase in perceived risk.

Revenue Growth: Lowered meaningfully from around 124.9% to approximately 111.6%, signaling tempered expectations for top line expansion.

Net Profit Margin: Trimmed slightly from about 16.98% to roughly 16.03%, indicating marginally lower long term profitability assumptions.

Future P/E: Edged down from roughly 36.6x to about 35.3x, suggesting a modest contraction in the valuation multiple applied to forward earnings.

Narratives on Simply Wall St connect the story behind a company to the numbers investors care about. They let you explain, or follow, how key events shape forecasts for revenue, earnings and margins, and how those forecasts roll up into a Fair Value. Hosted on the Community page used by millions of investors, Narratives update dynamically as news, trials and earnings land so you can compare Fair Value to the current price and decide when to buy or sell.

Head over to the Simply Wall St Community and follow the Narrative on Agios Pharmaceuticals to stay on top of:

How the upcoming FDA decision and global partnerships for PYRUKYND could expand long term revenue streams and earnings power.

Why analysts expect rapid revenue growth, rising margins and a higher future P/E multiple despite today’s volatility.

What could derail the story, from safety concerns and heavy spending to competitive threats and slower international uptake.

Read the full Agios Pharmaceuticals Narrative on Simply Wall St and make your own call on the numbers behind the story.

Curious how numbers become stories that shape markets? Explore Community Narratives

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include AGIO.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com